Skip to main content
Literatur
1.
Zurück zum Zitat Hübner T, Nickel T, Steinbeck G, Massberg S, Schramm R, Reichart B, Hagl C, Kiwi A, Weis M (2015) A single German center experience with intermittent inotropes for patients on the high-urgent heart transplant waiting list. Clin Res Cardiol [Epub ahead of print] Hübner T, Nickel T, Steinbeck G, Massberg S, Schramm R, Reichart B, Hagl C, Kiwi A, Weis M (2015) A single German center experience with intermittent inotropes for patients on the high-urgent heart transplant waiting list. Clin Res Cardiol [Epub ahead of print]
2.
Zurück zum Zitat Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M, SURVIVE Investigators (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297(17):1883–1891CrossRefPubMed Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M, SURVIVE Investigators (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297(17):1883–1891CrossRefPubMed
3.
Zurück zum Zitat Aranda JM Jr, Schofield RS, Pauly DF, Cleeton TS, Walker TC, Monroe VS Jr, Leach D, Lopez LM, Hill JA (2003) Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J 145(2):324–329CrossRefPubMed Aranda JM Jr, Schofield RS, Pauly DF, Cleeton TS, Walker TC, Monroe VS Jr, Leach D, Lopez LM, Hill JA (2003) Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J 145(2):324–329CrossRefPubMed
4.
Zurück zum Zitat Antila S, Sundberg S, Lehtonen LA (2007) Clinical pharmacology of levosimendan. Clin Pharmacokinet 46(7):535–552CrossRefPubMed Antila S, Sundberg S, Lehtonen LA (2007) Clinical pharmacology of levosimendan. Clin Pharmacokinet 46(7):535–552CrossRefPubMed
5.
Zurück zum Zitat Lehtonen LA, Antila S, Pentikäinen PJ (2004) Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 43(3):187–203CrossRefPubMed Lehtonen LA, Antila S, Pentikäinen PJ (2004) Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 43(3):187–203CrossRefPubMed
6.
Zurück zum Zitat Thackray S, Easthaugh J, Freemantle N, Cleland JG (2002) The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure: a meta-regression analysis. Eur J Heart Fail 4(4):515–529CrossRefPubMed Thackray S, Easthaugh J, Freemantle N, Cleland JG (2002) The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure: a meta-regression analysis. Eur J Heart Fail 4(4):515–529CrossRefPubMed
7.
Zurück zum Zitat Dixon JR Jr (1998) The international conference on harmonization good clinical practice guideline. Qual Assur 6(2):65–74PubMed Dixon JR Jr (1998) The international conference on harmonization good clinical practice guideline. Qual Assur 6(2):65–74PubMed
8.
Zurück zum Zitat Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW, Young JB, Rayburn BK, Rogers JG, DeMarco T, Leier CV (2007) Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 153(1):98–104CrossRefPubMed Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW, Young JB, Rayburn BK, Rogers JG, DeMarco T, Leier CV (2007) Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 153(1):98–104CrossRefPubMed
9.
Zurück zum Zitat Levine BS (2000) Intermittent positive inotrope infusion in the management of end-stage, low-output heart failure. J Cardiovasc Nurs 14(4):76–93CrossRefPubMed Levine BS (2000) Intermittent positive inotrope infusion in the management of end-stage, low-output heart failure. J Cardiovasc Nurs 14(4):76–93CrossRefPubMed
10.
Zurück zum Zitat Felker GM, O’Connor CM (2001) Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 142(3):393–401CrossRefPubMed Felker GM, O’Connor CM (2001) Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 142(3):393–401CrossRefPubMed
11.
Zurück zum Zitat Parissis JT, Adamopoulos S, Farmakis D et al (2006) Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 92:1768–1772PubMedCentralCrossRefPubMed Parissis JT, Adamopoulos S, Farmakis D et al (2006) Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 92:1768–1772PubMedCentralCrossRefPubMed
Metadaten
Titel
Intermittent inotrope therapy: evidence or belief?
verfasst von
Stephan Ensminger
Uwe Schulz
P. Christian Schulze
Friedrich-Wilhelm Mohr
Jan Gummert
Publikationsdatum
01.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 11/2015
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-015-0903-7

Weitere Artikel der Ausgabe 11/2015

Clinical Research in Cardiology 11/2015 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.